Danone reports Q1 revenue EUR 6.71B vs. EUR 6.84B last year

In Q1 2026, sales stood at EUR 6,708m, up +2.7% LFL, led by an increase of +1.5% in volume/mix and +1.2% in price. On a reported basis, sales decreased by -2.0%, negatively impacted by forex, mainly reflecting the depreciation of several currencies against the euro, notably the US dollar, the Argentine peso, the Indonesian rupiah and the Chinese renminbi. In addition, scope and contribution from hyperinflation both had a positive impact on reported sales. CEO Antoine de Saint-Affrique said, “This first quarter demonstrated again the resilience, strength and relevance of our health focused portfolio: against a challenging backdrop, we delivered a solid performance of +2.7% LFL, driven by positive volume/mix across all categories. Our winning platforms continued to perform strongly, notably in dairy with high protein, skyr and kefir, in Waters with evian and Mizone, as well as in medical nutrition around the globe. We accelerated our transformation with the signing of two transactions that will further strengthen our portfolio: the acquisition of Huel, extending our presence in the fast-growing complete nutrition space, and the creation of a dairy joint venture with Arcor, unlocking new opportunities in Argentina. Meanwhile, we remained constructively dissatisfied and focused on delivering on our priorities and addressing the areas that still require further progress. In a world that remains volatile and uncertain, we stay disciplined and fully focused on executing on our Renew strategy. We are confident in our science based, and consumer and patient centric approach and confirm our full year guidance.”